Evidence map›Paper›PMID 38268918›Full record

ArticleFrontiers in immunology2023

Persistence of KIR

Clara Di Vito, Nicolò Coianiz, Michela Calvi, Sara Terzoli, Elisa Zaghi, Simone Puccio, Alessandro Frigo, Jacopo Mariotti, Chiara De Philippis, Daniele Mannina and 8 more

Open access · goldAbstract read
In one paragraph

Article in Frontiers in immunology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.2field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 5 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 3 institutions in 2 countries.

Clara Di VitoUnit of Clinical and Experimental Immunology, IRCCS Humanitas Research Hospital, Rozzano, Milan, Italy.
Nicolò CoianizUnit of Clinical and Experimental Immunology, IRCCS Humanitas Research Hospital, Rozzano, Milan, Italy.
Michela CalviUnit of Clinical and Experimental Immunology, IRCCS Humanitas Research Hospital, Rozzano, Milan, Italy.
Sara TerzoliUnit of Clinical and Experimental Immunology, IRCCS Humanitas Research Hospital, Rozzano, Milan, Italy.
Elisa ZaghiUnit of Clinical and Experimental Immunology, IRCCS Humanitas Research Hospital, Rozzano, Milan, Italy.
Simone PuccioLaboratory of Translational Immunology, IRCCS Humanitas Research Hospital, Milan, Italy.
Alessandro FrigoUnit of Clinical and Experimental Immunology, IRCCS Humanitas Research Hospital, Rozzano, Milan, Italy.
Jacopo MariottiBone Marrow Transplant Unit, IRCCS Humanitas Research Hospital, Milan, Italy.
Chiara De PhilippisBone Marrow Transplant Unit, IRCCS Humanitas Research Hospital, Milan, Italy.
Daniele ManninaBone Marrow Transplant Unit, IRCCS Humanitas Research Hospital, Milan, Italy.
Barbara SarinaBone Marrow Transplant Unit, IRCCS Humanitas Research Hospital, Milan, Italy.
Rossana MineriMolecular Biology Section, Clinical Investigation Laboratory, IRCCS Humanitas Research Hospital, Milan, Italy.
Vu Thuy Khanh Le-TrillingInstitute for Virology, University Hospital Essen, University of Duisburg-Essen, Essen, Germany.
Mirko TrillingInstitute for Virology, University Hospital Essen, University of Duisburg-Essen, Essen, Germany.
Luca CastagnaBone Marrow Transplant Unit, IRCCS Humanitas Research Hospital, Milan, Italy.
Stefania BramantiBone Marrow Transplant Unit, IRCCS Humanitas Research Hospital, Milan, Italy.
Armando SantoroBone Marrow Transplant Unit, IRCCS Humanitas Research Hospital, Milan, Italy.
Domenico MavilioUnit of Clinical and Experimental Immunology, IRCCS Humanitas Research Hospital, Rozzano, Milan, Italy.
IRCCS Humanitas Research Hospital · ITUniversity of Duisburg-Essen · DEUniversity of Milan · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Haploidentical hematopoietic stem cell transplantation (h-HSCT) is a therapeutic option to cure patients affected by hematologic malignancies. The kinetics and the quality of immune-reconstitution (IR) impact the clinical outcome of h-HSCT and limit the onset of life-threatening Human Cytomegalovirus (HCMV) infection/reactivation. Natural Killer (NK) cells are the first lymphocytes that recover after h-HSCT and they can provide rapid innate immune responses against opportunistic pathogens. By performing a longitudinal single-cell analysis of multiparametric flow-cytometry data, we show here that the persistence at high frequencies of CD158b1b2j

Indexed as

Cytomegalovirus InfectionsHematologic NeoplasmsHematopoietic Stem Cell TransplantationCytomegalovirusHumansKiller Cells, Naturalhaploidentical hematopoietic stem cell transplantationhuman cytomegalovirusimmune reconstitutionnatural killer cellsviral immunity

Identifiers

PMID38268918
PMCPMC10806243
OpenAlexW4390698989

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.